We have found that EGR1 remains stable, or slightly increased, in the NBM and the prefrontal cortex (PFC) in early AD stages, possibly contributing to stimulating neuronal activity in early AD and thereby preventing early symptomatology (Zhu et al., 2016; Hu et al., 2019). This evidence concerns the gene EGR1 and Alzheimer disease.